{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:18:47Z","timestamp":1790245127191,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40264-015-0337-1","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T10:19:29Z","timestamp":1441275569000},"page":"1179-1186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase\u00ae"],"prefix":"10.1007","volume":"38","author":[{"given":"Thi-Thanh Loan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Palmaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Moulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"337_CR1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMct1014202","volume":"365","author":"P Imbach","year":"2011","unstructured":"Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365:734\u201341.","journal-title":"N Engl J Med."},{"key":"337_CR2","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Summary review, Nplate\u00ae. 2008. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist . Accessed 30 Sept 2014."},{"key":"337_CR3","unstructured":"US Food and Drug Administration Center for Drug Evaluation and Research. Summary review, Promacta\u00ae. 2008. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist . Accessed 30 Sept 2014."},{"key":"337_CR4","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use assessment report for Nplate. 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000942\/WC500039475.pdf . Accessed 30 Sept 2014."},{"key":"337_CR5","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use assessment report for Revolade. 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/001110\/WC500089967.pdf . Accessed 30 Sept 2014."},{"key":"337_CR6","unstructured":"US Food and Drug Administration Departement of Health and Human Services. Supplement approval for Promacta. 2012. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo . Accessed 30 Sept 2014."},{"key":"337_CR7","unstructured":"European Medicines Agency. CHMP group of an extension of marketing authorisation and variations assessment report, Revolade\u00ae. 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/001110\/WC500152310.pdf . Accessed 30 Sept 2014."},{"key":"337_CR8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","volume":"371","author":"DJ Kuter","year":"2008","unstructured":"Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395\u2013403.","journal-title":"Lancet."},{"key":"337_CR9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","volume":"377","author":"G Cheng","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase\u00a03 study. Lancet. 2011;377:393\u2013402.","journal-title":"Lancet."},{"key":"337_CR10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","volume":"121","author":"MN Saleh","year":"2013","unstructured":"Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121:537\u201345.","journal-title":"Blood."},{"key":"337_CR11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","volume":"161","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ, Bussel JB, Newland A, Baker RI, Lyons RM, Wasser J, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161:411\u201323.","journal-title":"Br J Haematol."},{"key":"337_CR12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1538-7836.2010.03830.x","volume":"8","author":"TB Gernsheimer","year":"2010","unstructured":"Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010;8:1372\u201382.","journal-title":"J Thromb Haemost."},{"key":"337_CR13","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/blood-2011-03-340166","volume":"118","author":"M Khellaf","year":"2011","unstructured":"Khellaf M, Michel M, Quittet P, Viallard J-F, Alexis M, Roudot-Thoraval F, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118:4338\u201345.","journal-title":"Blood."},{"key":"337_CR14","first-page":"586","volume":"100","author":"L Garabet","year":"2015","unstructured":"Garabet L, Lee S, Mowinckel M-C, Jonassen C, Liebman H, Bussel J, et al. Effect of thrombopoietin receptor agonists on coagulation and platelet activation in patients with immune thrombocytopenia. Haematologica. 2015;100:586.","journal-title":"Haematologica."},{"key":"337_CR15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.exphem.2009.06.011","volume":"37","author":"JA Erhardt","year":"2009","unstructured":"Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in\u00a0vitro platelet function. Exp Hematol. 2009;37:1030\u20137.","journal-title":"Exp Hematol."},{"key":"337_CR16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.2012.074633","volume":"98","author":"M Khellaf","year":"2013","unstructured":"Khellaf M, Viallard J-F, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98:881\u20137.","journal-title":"Haematologica."},{"issue":"1","key":"337_CR17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/bjh.13266","volume":"169","author":"JR Gonz\u00e1lez-Porras","year":"2015","unstructured":"Gonz\u00e1lez-Porras JR, Mingot-Castellano ME, Andrade MM, Alonso R, Caparr\u00f3s I, Arratibel MC, et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. 2015;169(1):111\u20136.","journal-title":"Br J Haematol."},{"key":"337_CR18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ejim.2014.09.006","volume":"25","author":"G Moulis","year":"2014","unstructured":"Moulis G, Bagheri H, Sailler L, Jonville-Bera A-P, Weber E, Guy C, et al. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009\u20132013 French pharmacovigilance assessment. Eur J Intern Med. 2014;25:777\u201380.","journal-title":"Eur J Intern Med."},{"key":"337_CR19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J."},{"key":"337_CR20","unstructured":"World Health Organization Uppsala Monitoring Centre. Pharmacovigilance: ensuring the safe use of medicines\u2014WHO policy perspectives on medicines. 2004. http:\/\/apps.who.int\/medicinedocs\/fr\/d\/Js6164e . Accessed 30 Sept 2014."},{"key":"337_CR21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 1999;20:109\u201317.","journal-title":"Drug Saf."},{"key":"337_CR22","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Introductory guide for standardised MedDRA queries (SMQs). http:\/\/www.meddra.org\/how-to-use\/support-documentation\/english . Accessed 30 Sept 2014."},{"key":"337_CR23","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u20138.","journal-title":"Br J Clin Pharmacol."},{"key":"337_CR24","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2141.2010.08234.x","volume":"150","author":"J Thachil","year":"2010","unstructured":"Thachil J, Callaghan T, Martlew V. Thromboembolic events are not uncommon in patients with immune thrombocytopenia. Br J Haematol. 2010;150:496\u20137.","journal-title":"Br J Haematol."},{"key":"337_CR25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s11239-014-1050-0","volume":"38","author":"HR Yusuf","year":"2014","unstructured":"Yusuf HR, Hooper WC, Beckman MG, Zhang QC, Tsai J, Ortel TL. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases. J Thromb Thrombolysis. 2014;38:306\u201313.","journal-title":"J Thromb Thrombolysis."},{"key":"337_CR26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3747\/co.21.1864","volume":"21","author":"E Donnellan","year":"2014","unstructured":"Donnellan E, Kevane B, Bird BRH, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol. 2014;21:134\u201343.","journal-title":"Curr Oncol."},{"key":"337_CR27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","volume":"16","author":"D Paran","year":"2005","unstructured":"Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16:313\u20138.","journal-title":"Blood Coagul Fibrinolysis."},{"key":"337_CR28","unstructured":"Stephen M. Introduction. Stephens\u2019 detection and evaluation of adverse drug reactions. 6th ed. Chichester: Wiley; 2014. p. 14."},{"key":"337_CR29","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/BF03261980","volume":"35","author":"G Durrieu","year":"2012","unstructured":"Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, et al. First French experience of ADR reporting by patients after a mass immunization campaign with influenza\u00a0A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals. Drug Saf. 2012;35:845\u201354.","journal-title":"Drug Saf."},{"key":"337_CR30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s40264-014-0203-6","volume":"37","author":"A Pages","year":"2014","unstructured":"Pages A, Bondon-Guitton E, Montastruc JL, Bagheri H. Undesirable effects related to oral antineoplastic drugs: comparison between patients\u2019 internet narratives and a national pharmacovigilance database. Drug Saf. 2014;37:629\u201337.","journal-title":"Drug Saf."},{"key":"337_CR31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1046\/j.1365-2125.1999.00881.x","volume":"47","author":"C Pierfitte","year":"1999","unstructured":"Pierfitte C, B\u00e9gaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47:329\u201331.","journal-title":"Br J Clin Pharmacol."},{"key":"337_CR32","unstructured":"Weber J. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in inflammation research. New\u00a0York: Raven; 1984. p. 1\u20137."},{"key":"337_CR33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2125.1997.t01-1-00573.x","volume":"44","author":"F Haramburu","year":"1997","unstructured":"Haramburu F, B\u00e9gaud B, Moride Y. Temporal trends in spontaneous reporting of unlabelled adverse drug reactions. Br J Clin Pharmacol. 1997;44:299\u2013301.","journal-title":"Br J Clin Pharmacol."},{"key":"337_CR34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.2012.04185.x","volume":"74","author":"G Moulis","year":"2012","unstructured":"Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc J-L, et al. Trends of reporting of \u201cserious\u201d vs. \u201cnon-serious\u201d adverse drug reactions over time: a study in the French pharmacovigilance database. Br J Clin Pharmacol. 2012;74:201\u20134.","journal-title":"Br J Clin Pharmacol."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-015-0337-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0337-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T22:22:12Z","timestamp":1718058132000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-015-0337-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0337-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]}}}